Adverse event onset rates were 16.3 % ( 40 of 246 subjects ) and 10.0 % ( 25 of 251 subjects ) in the diquafosol group and HA group , respectively , with borderline significant intergroup differences ( p = 0.046 ) , while adverse drug reaction incidence rates were 12.2 % ( 30 of 246 subjects ) and 6.0 % ( 15 of 251 subjects ) , respectively ( p = 0.019 ) .